Filing Details
Actinium Pharmaceuticals, Inc. (AMEX:ATNM) filed a Form 8-K with the Securities and Exchange Commission on October 15, 2026, disclosing a material event.
8k filedAMEX:ATNM
Actinium Pharmaceuticals, Inc. (ATNM) Reports Material Event to SEC
Actinium Pharmaceuticals, Inc. (AMEX:ATNM) filed a Form 8-K with the Securities and Exchange Commission on October 15, 2026, disclosing a material event.
At publication ·
What changed
Actinium Pharmaceuticals, Inc. (AMEX:ATNM) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Actinium Pharmaceuticals filed a Form 8-K with the SEC on October 15, 2026, disclosing an unspecified material event.
- The healthcare company's stock trades at $1.06 with a market capitalization of $45.5 million.
- Form 8-K filings report material events such as leadership changes, agreements, acquisitions, or asset sales between regular reports.
Market Context
Actinium Pharmaceuticals, Inc.'s stock currently trades at $1.06 with a market capitalization of $45.5M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Actinium Pharmaceuticals, Inc.'s stock.
All SEC filings for Actinium Pharmaceuticals, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View ATNM Stock Page
Frequently Asked Questions
Where can I read ATNM's SEC filings?
Browse all filings on our ATNM SEC filings page.
What types of SEC filings does Actinium Pharmaceuticals, Inc. file?
Public companies like Actinium Pharmaceuticals, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.
